Validation of erythropoietin use data on Medicare's End-Stage Renal Disease Medical Evidence Report.
|Article Type:||Brief article|
Erythropoietin (Health aspects)
Anemia (Risk factors)
|Author:||Fischer, Michael J.|
|Publication:||Name: Journal of Rehabilitation Research & Development Publisher: Department of Veterans Affairs Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2010 Department of Veterans Affairs ISSN: 0748-7711|
|Issue:||Date: Dec 30, 2010 Source Volume: 47 Source Issue: 8|
|Topic:||Event Code: 260 General services Computer Subject: Company systems management|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Veterans are at high risk for developing kidney disease, and those
who develop the disease have extremely high morbidity and mortality
rates. Anemia is a frequent complication of kidney disease and leads to
poor health. To treat anemia successfully in veterans, physicians
administer erythropoiesis-stimulating agents (ESAs). Much of the prior
research investigating the relationship between ESAs, anemia, and kidney
disease is based on information from Medicare's Medical Evidence
Report (Form 2728). Before this study, the accuracy of the information
on Form 2728 was not known. This study found significant errors in ESA
information reported on Form 2728, which could have led to biased
findings and misunderstandings in prior research. Recognition of these
shortcomings of Form 2728 will benefit researchers because they will be
able to conduct better studies of this matter in the future.
Michael J. Fischer, MD, MSPH, et al.
|Gale Copyright:||Copyright 2010 Gale, Cengage Learning. All rights reserved.|